Neuropace, Inc. Common Stock
NPCEStock
$16.47+73.37%52W
Market Cap$561.52M
P/E—
Div yield—
Beta1.95
Price Chart
Favorite Metrics
Price vs S&P 500 (26W)-12.97%
Price vs S&P 500 (4W)7.33%
VGM Score48.47
Market Capitalization$561.52M
Earnings Surprise History
Q1 26-0.20est. -0.23
Analyst Recommendations
Mar 2026
Apr 2026
May 2026
Jun 2026
4.21
4.21
4.21
4.21
Industry Peers — Surgical & Medical Instruments(141)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
NPCENeuropace, Inc. Common Stock | D | C | B | $16.47 |
| SYKStryker Corporation | C | C | D | $331.20 |
| MMM3M Company | C | F | B | $161.77 |
| BSXBoston Scientific Corp. | C | B | F | $44.62 |
| MDLNMedline Inc. Class A common stock | C | D | D | $41.11 |
| BDXBecton, Dickinson and Co. | B | C | B | $159.93 |
| DXCMDexCom, Inc. | C | B | C | $77.98 |
| RMDResMed Inc. | C | B | D | $202.76 |
| WSTWest Pharmaceutical Services, Inc. | D | C | A | $362.44 |
| SOLVSolventum Corporation | C | D | B | $81.70 |
| PENPenumbra, Inc. | F | C | B | $319.60 |
About
NeuroPace develops implantable neuromodulation systems to treat epilepsy through its RNS System, which continuously monitors brain electrical activity and delivers personalized seizure prevention therapy. The company's comprehensive platform integrates implantable devices, clinical monitoring software, and patient management tools that support ongoing treatment outcomes. NeuroPace generates revenue from device sales, implantation procedures, and subscription-based patient management services.